937633-19-7

Basic information

• Product Name: 2-(chloromethyl)-5-(2,4-difluorophenyl)-1,3,4-oxadiazole
• Synonyms: 2-(chloromethyl)-5-(2,4-difluorophenyl)-1,3,4-oxadiazole
• CAS NO: 937633-19-7
• Molecular Formula: C9H5ClF2N2O
• Molecular Weight: 230.5986064
• Mol File: 937633-19-7.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-(chloromethyl)-5-(2,4-difluorophenyl)-1,3,4-oxadiazole(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(chloromethyl)-5-(2,4-difluorophenyl)-1,3,4-oxadiazole(937633-19-7)
• EPA Substance Registry System: 2-(chloromethyl)-5-(2,4-difluorophenyl)-1,3,4-oxadiazole(937633-19-7)

Safety Data

• Hazardous Substances Data: 937633-19-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-(chloromethyl)-5-(2,4-difluorophenyl)-1,3,4-oxadiazole is used as a potential therapeutic agent for its anticancer properties. It has been studied for its ability to target and inhibit the growth of cancer cells, making it a candidate for further research and development in cancer treatment.
Used in Antiviral Applications:
In the field of virology, 2-(chloromethyl)-5-(2,4-difluorophenyl)-1,3,4-oxadiazole is used as a potential antiviral agent. Its activity against certain viruses is currently under investigation, with the aim of developing new treatments to combat viral infections.
Used in Enzyme Inhibition:
2-(chloromethyl)-5-(2,4-difluorophenyl)-1,3,4-oxadiazole is used as an enzyme inhibitor, specifically targeting the human Pin1 protein. This application is significant in the context of diseases where the inhibition of such enzymes can lead to therapeutic benefits, and further research is being conducted to explore its full potential in this area.

Upstream product

• 1583-58-0 2,4-difluoro-benzoic acid 
• 118737-62-5 2,4-difluorobenzoic acid hydrazide 
• 79-11-8 chloroacetic acid 

Relevant articles and documents

Design, synthesis, and evaluation of N-benzylpyrrolidine and 1,3,4-oxadiazole as multitargeted hybrids for the treatment of Alzheimer's disease

Novel N-Benzylpyrrolidine hybrids were designed, synthesized, and tested against multiple in-vitro and in-vivo parameters. Among all the synthesized molecules, 8f and 12f showed extensive inhibition against beta-secretase-1 (hBACE-1), human acetylcholinesterase (hAChE) & human butyrylcholinesterase (hBuChE). These molecules are also endowed with significant AChE-peripheral anionic site (PAS) binding capability, blood-brain barrier permeability, potential disassembly of Aβ aggregates along with neuroprotection ability on SHSY-5Y cell lines. Results of the Y-Maze and Morris water maze test concluded that compounds 8f and 12f ameliorated cognitive dysfunction induced by scopolamine and Aβ. The ex-vivo activity was executed on rat's brain homogenate indicating a reduction in AChE level and oxidative stress. The pharmacokinetic investigation ascertained considerable oral absorption profile of the lead 12f. The results of the in silico docking studies and molecular dynamics simulations demonstrated stable interactions of compounds 8f and 12f with the target residues of hAChE, hBuChE and hBACE-1.

Novel Molecular Hybrids of N-Benzylpiperidine and 1,3,4-Oxadiazole as Multitargeted Therapeutics to Treat Alzheimer's Disease

Multitargeted hybrids of N-benzylpiperidine and substituted 5-phenyl-1,3,4-oxadiazoles were designed, synthesized, and evaluated against Alzheimer's disease (AD). Tested compounds exhibited moderate to excellent inhibition against human acetylcholinesterase (hAChE), butyrylcholinesterase (hBChE), and beta-secretase-1 (hBACE-1). The potential leads 6g and 10f exhibited balanced inhibitory profiles against all the targets, with a substantial displacement of propidium iodide from the peripheral anionic site of hAChE. Hybrids 6g and 10f also elicited favorable permeation across the blood-brain barrier and were devoid of neurotoxic liability toward SH-SY5Y neuroblastoma cells. Both leads remarkably disassembled Aβ aggregation in thioflavin T-based self- and AChE-induced experiments. Compounds 6g and 10f ameliorated scopolamine-induced cognitive dysfunctions in the Y-maze test. The ex vivo studies of rat brain homogenates established the reduced AChE levels and antioxidant activity of both compounds. Compound 6g also elicited noteworthy improvement in Aβ-induced cognitive dysfunctions in the Morris water maze test with downregulation in the expression of Aβ and BACE-1 proteins corroborated by Western blot and immunohistochemical analysis. The pharmacokinetic study showed excellent oral absorption characteristics of compound 6g. The in silico molecular docking and dynamics simulation studies of lead compounds affirmed their consensual binding interactions with PAS-AChE and aspartate dyad of BACE-1.